Where can I confirm pricing?

Always confirm final pricing directly with the provider. Prices change frequently. US Telehealth Review verifies provider pricing monthly but the provider's own pricing page is the authoritative source.

Is this medical advice?

No. US Telehealth Review provides educational information only. Always consult a licensed clinician before starting, changing, or stopping any medication.

BMI Eligibility for Semaglutide Weight Management

Overview

Wegovy label: BMI ≥30, or BMI ≥27 with weight-related comorbidity. 2024 expansion: adults with overweight/obesity + established CVD (no BMI floor for CV indication).

Related guides

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing

Verified pricing & the cost that matters

Across the July 2026 audit, compounded semaglutide spans about $79–$289 and tirzepatide $129–$349 per month. NexLife's flat $119/$139 (visits, shipping, labs included) is our pick for lowest predictable spend among fully transparent programs, though Embody is the cheaper raw sticker.

Verified compounded starting price, July 2026 (★ = Editor's Pick).

Watch the gap between the starter rate and the maintenance rate. Both drugs escalate over weeks, so tiered plans get more expensive at maintenance while a flat plan stays level (near $1,428/year at $119/month). Compare annualized cost at your effective dose, not the entry price.

What the evidence shows

Trial evidence keeps expectations realistic: semaglutide ~14.9% (STEP 1) and ~15.2% sustained (STEP 5); tirzepatide ~20.9% (SURMOUNT-1) and a decisive head-to-head win in SURMOUNT-5 (20.2% vs 13.7%). SELECT found a 20% cardiovascular-event reduction on semaglutide.

Cost aside, suitability is a clinical decision. Compounded GLP-1s are not FDA-approved, and a clinician must weigh the boxed thyroid C-cell warning, MTC/MEN2 history, and pregnancy before treatment.

How we rank. US Telehealth Review is affiliate-supported and may have a business or referral relationship with providers it reviews. Rankings are editorial; providers cannot pay for placement. Compounded GLP-1 medications are not FDA-approved. Details checked July 2026 — verify with each provider. Not medical advice.